BioCentriq is a cell and gene therapy development and manufacturing center.
BioCentriq has raised $29.2M in total funding. The most recent round was Series A. The last funding was announced in January 2024.
BioCentriq's investors include National Institute for Innovation in Manufacturing Biopharmaceuticals.
BioCentriq is headquartered in Newark, United States.
BioCentriq is a cell and gene therapy development and manufacturing center.
BioCentriq is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BioCentriq — Funding & Investors." VCBacked, January 3, 2024, https://www.vcbacked.co/company/biocentriq. Accessed October 31, 2026.
VCBacked. (2024). BioCentriq — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/biocentriq
{{cite web |title=BioCentriq — Funding & Investors |url=https://www.vcbacked.co/company/biocentriq |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated